AngioDynamics (ANGO) AI Stock Analysis

• Market Cap: $415.41M
• Dividend Yield: N/A
• Average Volume (3M): 585.28K
• Price to Earnings (P/E): ―
• Beta (1Y): 0.26
• Revenue Growth: -12.56%
• EPS Growth: 78.70%
• Country: US
• Employees: 748
• Sector: Healthcare
• Sector Strength: 48
• Industry: Medical - Instruments & Supplies
• EPS (TTM): -0.08
• Shares Outstanding: 40,606,987
• 10 Day Avg. Volume: 676,290
• 30 Day Avg. Volume: 585,280
• PEG Ratio: -0.07
• Price to Book (P/B): 0.99
• Price to Sales (P/S): 0.00
• P/FCF Ratio: -87.39
• Enterprise Value/Market Cap: 0.91
• Enterprise Value/Revenue: 0.32
• Enterprise Value/Gross Profit: 2.50
• Enterprise Value/Ebitda: -6.78
• 1Y Price Target: $15.50
• Price Target Upside: 54.69% Upside
• Rating Consensus: Moderate Buy
• Number of Analyst Covering: 2

• Rating: 56 Neutral
• Price Target: $11.50 ▲(14.77%Upside)

AngioDynamics' overall stock score reflects financial struggles, despite positive momentum and strategic initiatives. The company's improved guidance and strong segment growth are offset by ongoing profitability and cash flow issues.

Positive Factors

Market Expansion Opportunities

ANGO's stock is undervalued for the access to multiple high-growth markets it already has, along with the potential further upside from its ability to enter both DVT and coronary markets in the future.

Product Differentiation

The company's AlphaVac is differentiated from its competition in a variety of ways, including saving procedure time and having features like a funnel shaped tip which can remove more clot burden.

Regulatory Approval

The FDA clearance should enable the company to expand the commercial footprint of NanoKnife, which could help drive the company’s Med Tech sales growth.

Negative Factors

Market Maturity

ANGO should see continued growth in Auryon, but likely more moderated comparatively over the long term given atherectomy is a mature market.

Potential Market Dilution

With the company inching closer to sustained profitability, any potential dilution overhang on the stock is likely abating.

AngioDynamics Business Overview & Revenue Model

Company Description

AngioDynamics, Inc. is a leading provider of innovative medical devices used for the minimally invasive treatment of cancer and peripheral vascular disease. The company operates primarily in the healthcare sector, specializing in the development, manufacture, and sale of medical, surgical, and diagnostic devices that advance the care of patients by enhancing the quality of healthcare. Its core products include radiofrequency ablation systems, laser systems, vascular access products, and fluid management systems, catering to a diverse range of healthcare providers across the globe.

How the Company Makes Money

AngioDynamics makes money through the sale of its medical devices and technology solutions to hospitals, clinics, and healthcare providers. The company's revenue model is centered around manufacturing and distributing its proprietary products, which are used in the treatment of cancer and vascular diseases. Key revenue streams include sales of products like the NanoKnife System for ablative procedures, the AngioVac System for thrombus management, and its line of vascular access products. Additionally, the company forms significant partnerships with healthcare institutions and professionals to expand its market reach and enhance product adoption. AngioDynamics also invests in research and development to innovate and improve its product offerings, which helps maintain its competitive edge in the medical device industry.

AngioDynamics Financial Statement Overview

Summary

AngioDynamics faces significant financial challenges, with declining revenues, persistent losses, and cash flow difficulties, despite maintaining a low leverage position.

Income Statement

AngioDynamics shows a declining revenue trend over recent years, with the latest TTM revenue at $283.32M, down from $303.91M in 2024. The gross profit margin remains stable at around 53%, but the company struggles with profitability, reflected in significant negative EBIT and net income margins. The net loss has increased to $41.39M in TTM, showing a concerning trajectory.

Balance Sheet

The balance sheet displays moderate stability with a low debt-to-equity ratio of 0.03 in TTM, indicating minimal leverage. However, the equity ratio has decreased from 64% in 2023 to 65% in TTM, reflecting reduced shareholder equity. Despite a decline in total assets, the company maintains a healthy cash position.

Cash Flow

Cash flow analysis reveals challenges, as AngioDynamics reports negative operating and free cash flows. Although the free cash flow deficit has slightly reduced, the negative operating cash flow suggests cash management issues. The company's ability to convert net income to cash flow remains weak.

Breakdown
TTM	Jun 2024	Jun 2023	Jun 2022	Jun 2021	Jun 2020
Income Statement		Total Revenue
283.32M	303.91M	338.75M	316.22M	291.01M	264.16M
	Gross Profit
151.43M	154.70M	174.25M	165.73M	156.79M	150.27M
	EBIT
-25.46M	-192.44M	-19.23M	-19.01M	-14.87M	-14.17M
	EBITDA
-7.79M	-14.29M	12.19M	11.13M	-8.90M	-143.74M
	Net Income Common Stockholders
-41.39M	-184.35M	-52.44M	-26.55M	-31.55M	-165.79M
Balance Sheet		Cash, Cash Equivalents and Short-Term Investments
44.76M	76.06M	44.62M	28.82M	48.16M	54.44M
	Total Assets
285.42M	317.67M	532.64M	552.75M	561.44M	595.51M
	Total Debt
5.00M	5.91M	49.82M	33.78M	20.00M	40.84M
	Net Debt
-39.76M	-71.33M	5.20M	4.96M	-28.16M	-13.60M
	Total Liabilities
99.55M	112.08M	154.34M	128.26M	121.98M	139.64M
	Stockholders Equity
185.87M	205.59M	378.30M	424.49M	439.46M	455.87M
Cash Flow		Free Cash Flow
-33.21M	-33.93M	-4.27M	-11.49M	10.38M	-22.14M
	Operating Cash Flow
-23.94M	-28.16M	78.00K	-7.19M	24.09M	-14.55M
	Investing Cash Flow
-9.89M	123.72M	-9.75M	-19.31M	-13.71M	-63.34M
	Financing Cash Flow
515.00K	-64.25M	25.42M	7.68M	-16.99M	-95.24M

AngioDynamics Technical Analysis

• Technical Analysis Sentiment: Neutral
• Last Price: 10.02
• 50DMA: Positive
• 100DMA: Positive
• 200DMA: Positive
• MACD: Positive
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For ANGO, the sentiment is Neutral. The current price of 10.02 is below the 20-day moving average (MA) of 10.43, above the 50-day MA of 9.79, and above the 200-day MA of 8.99, indicating a neutral trend. The MACD of 0.20 indicates Positive momentum. The RSI at 46.10 is Neutral, neither overbought nor oversold. The STOCH value of 20.80 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for ANGO.

AngioDynamics Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
MMSI	76 Outperform	$5.49B	45.11	9.16%	―	8.24%	18.54%
LMAT	70 Outperform	$1.85B	41.31	13.77%	0.98%	13.19%	31.73%
ICUI	68 Neutral	$3.16B	―	-4.62%	―	7.19%	-56.19%
TFX	58 Neutral	$5.20B	37.10	3.48%	1.16%	0.29%	-48.98%
ANGO	56 Neutral	$415.41M	―	-20.46%	―	-12.56%	78.70%
STAA	54 Neutral	$834.52M	55.81	-19.14%	―	-14.44%	-557.38%
Sector *	53 Neutral	$5.24B	3.32	-44.36%	6.63%	16.78%	-0.12%

AngioDynamics Corporate Events

AngioDynamics Secures $25M Credit Facility with JPMorgan

On May 28, 2025, AngioDynamics, Inc. entered into a new Credit Agreement with JPMorgan Chase Bank, N.A., securing a $25 million revolving credit facility. This agreement is intended to provide financial flexibility for the company during its manufacturing transfer process, supporting its strategic growth without impacting its operations. The facility includes a maturity date of May 28, 2027, and is secured by the company’s assets, with specific financial covenants and guarantees from its subsidiary, RITA Medical Systems, LLC.

The most recent analyst rating on (ANGO) stock is a Buy with a $14.00 price target. To see the full list of analyst forecasts on AngioDynamics stock, see the ANGO Stock Forecast page.

AngioDynamics to Host Virtual Cardiovascular Investor Event

On April 2, 2025, AngioDynamics will host a virtual Cardiovascular Investor Event, highlighting its innovative technologies and improved patient outcomes in cardiovascular care. The event underscores AngioDynamics’ strategic focus on growth within the high-growth cardiovascular disease market, leveraging its comprehensive portfolio and differentiated technologies to strengthen its competitive position.

AngioDynamics Reports Strong Q3 2025 Financial Results

AngioDynamics reported its fiscal third quarter 2025 results, highlighting a 9.2% increase in net sales to $72.0 million, driven by a 22.2% growth in MedTech sales. The company achieved a GAAP gross margin of 54.0% and improved its adjusted EBITDA to $1.3 million, reflecting strategic focus on MedTech markets. Key developments include FDA clearance for the NanoKnife System for prostate tissue ablation and the initiation of the AMBITION BTK trial for the Auryon Atherectomy System. AngioDynamics also secured a $25 million revolving line of credit from J.P. Morgan, enhancing financial flexibility.